S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
Log in

BioNTech Stock Price, Forecast & Analysis (NASDAQ:BNTX)

$21.33
+1.65 (+8.38 %)
(As of 11/22/2019 04:00 PM ET)
Today's Range
$20.44
Now: $21.33
$21.80
50-Day Range N/A
52-Week Range
$12.52
Now: $21.33
$22.00
Volume2,651 shs
Average Volume145,314 shs
Market Capitalization$4.83 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company was founded in 2008 and is headquartered in Mainz, Germany.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BNTX
CUSIPN/A
CIKN/A
Phone49-61-31908-40

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees1,179
Market Cap$4.83 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive BNTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.


BioNTech (NASDAQ:BNTX) Frequently Asked Questions

What is BioNTech's stock symbol?

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

What price target have analysts set for BNTX?

8 brokers have issued 1 year target prices for BioNTech's shares. Their forecasts range from $21.00 to $25.00. On average, they expect BioNTech's stock price to reach $22.17 in the next twelve months. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Price Targets for BioNTech.

What is the consensus analysts' recommendation for BioNTech?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioNTech.

Has BioNTech been receiving favorable news coverage?

News headlines about BNTX stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioNTech earned a news impact score of -1.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for BioNTech.

Who are some of BioNTech's key competitors?

What other stocks do shareholders of BioNTech own?

Who are BioNTech's key executives?

BioNTech's management team includes the folowing people:
  • Prof. Ugur Sahin M.D., CEO & Member of Management Board (Age 54)
  • Dr. Sierk Pötting, CFO, COO & Member of Management Board (Age 46)
  • Mr. Sean Marett, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board (Age 54)
  • Dr. Özlem Türeci, Chief Medical Officer & Member of Management Board (Age 52)
  • Sabine Steimle, Head Global Communications

When did BioNTech IPO?

(BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

When did the company's quiet period expire?

BioNTech's quiet period expired on Tuesday, November 19th. BioNTech had issued 10,000,000 shares in its public offering on October 10th. The total size of the offering was $150,000,000 based on an initial share price of $15.00. During the company's quiet period, insiders and underwriters that worked on the IPO were restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of BioNTech?

Shares of BNTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioNTech's stock price today?

One share of BNTX stock can currently be purchased for approximately $21.33.

How big of a company is BioNTech?

BioNTech has a market capitalization of $4.83 billion. BioNTech employs 1,179 workers across the globe.View Additional Information About BioNTech.

What is BioNTech's official website?

The official website for BioNTech is http://www.biontech.de/.

How can I contact BioNTech?

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company can be reached via phone at 49-61-31908-40 or via email at [email protected]


MarketBeat Community Rating for BioNTech (NASDAQ BNTX)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  18
MarketBeat's community ratings are surveys of what our community members think about BioNTech and other stocks. Vote "Outperform" if you believe BNTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Featured Article: Arbitrage

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel